Target, Home Depot,...
Health Care: Drugs
Exelixis Inc. (EXEL: NASDAQ)
$4.55 0.00 | 0.00%
05/17/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -147.64M | 75.70M | -92.33M | -139.56M |
| Operating Gains/Losses | -950.00K | -2.25M | -8.20M | 7.77M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 27.04M | -24.29M | 5.97M | -8.50M |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 6.32M | -5.56M | -9.44M | 9.01M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | -40.23M | -245.59M | -38.79M | 86.91M |
| Other Non-Cash Items | 13.62M | 25.39M | 31.27M | 24.52M |
| Net Cash From Continuing Operations | -123.15M | -159.23M | -101.05M | -14.59M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -123.15M | -159.23M | -101.05M | -14.59M |
| Sale of Property, Plant & Equipment | 1.94M | 1.53M | 165.00K | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 55.20M | 140.35M | 50.53M |
| Purchases of Property, Plant & Equipment | -2.72M | -991.00K | -1.81M | -5.91M |
| Acquisitions | 0.00 | 3.01M | 9.00M | 2.20M |
| Purchases of Short-Term Investments | 0.00 | 0.00 | -167.32M | -161.17M |
| Other Cash from Investing Activities | 5.50M | -110.21M | 0.00 | -2.43M |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -259.47M | -51.46M | -19.57M | -112.32M |
| Issuance of Debt | 277.67M | 2.59M | 165.01M | 5.00M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 205.62M | 193.54M | 5.82M | 4.10M |
| Repayment of Long-Term Debt | -4.87M | -8.62M | -39.56M | -43.06M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | -25.00K |
| Net Cash From Financing Activities | 478.43M | 187.51M | 131.26M | -33.99M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 95.81M | -23.18M | 10.64M | -160.90M |
Portfolios with EXEL
- Portfolio NameUser Type
- ContributorDrugs Facing FDA Approval i...
- ContributorStocks Under-$10 Setting Up...
- ContributorMost-Active Stocks for the ...
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Stocks That Could Rise i...
- Contributor10 Biotech Stocks Loved and...
- Contributor10 Biotech Trades for Secon...
- UserMy Portfolio
- ContributorCancer Drug Stocks to Trade...
- Userbarry216 Portfolio 1
Latest EXEL Headlines from TheStreet
- EXEL Crosses Above Key Moving Average Level 05.08.13 | 04:05 pm
- 'Mad Money' Lightning Round: Buy, Buy, Buy Toll Brothers 04.17.13 | 06:04 am
- Exelixis Inc. Stock Downgraded (EXEL) 02.27.13 | 04:02 am
- Arena Pharmaceuticals And 6 More Stocks To Watch 01.07.13 | 07:01 pm
- Shorting Alexza Pharma On FDA's Adasuve Approval 12.19.12 | 07:12 am
- Exelixis Scores FDA Approval For Thyroid Cancer Drug 11.29.12 | 04:11 pm
- 'Mad Money' Lightning Round: Buy Philips 66 and Sprint 11.27.12 | 06:11 am
- Cramer's 'Mad Money' Recap: A Tale of Two Markets 11.26.12 | 07:11 pm
- Exelixis Preps For Thyroid Cancer Drug Approval 11.26.12 | 10:11 am
- Cramer's 'Mad Money' Recap: Good Reasons to Stay in the Market 11.13.12 | 07:11 pm
Press Releases for EXEL
- Exelixis Announces Webcast Of March 4 Presentation At The 33rd Annual Cowen Health Care Conference - Business Wire 02.25.13 | 04:02 pm
- Exelixis Selects Swedish Orphan Biovitrum AB As COMETRIQ™ European Distributor For Medullary Thyroid Cancer - Business Wire 02.21.13 | 04:02 pm
- Exelixis Announces Fourth Quarter And Full Year 2012 Financial Results - Business Wire 02.21.13 | 04:02 pm
- Exelixis Announces February 21st Webcast Of Fourth Quarter And Full Year 2012 Financial Results Conference Call - Business Wire 02.07.13 | 04:02 pm
- Exelixis Announces Webcast Of February 12th Presentation At The 15th Annual BIO CEO & Investor Conference - Business Wire 02.06.13 | 05:02 pm
- Exelixis Announces COMETRIQ™ (cabozantinib) Is Now Available In The U.S. - Business Wire 01.24.13 | 11:01 am
- Exelixis Announces Webcast Of January 9 Presentation At The J.P. Morgan 31st Annual Healthcare Conference - Business Wire 12.13.12 | 04:12 pm
- Exelixis Announces EMA Acceptance Of Marketing Authorization Application For COMETRIQ™ (cabozantinib) - Business Wire 11.29.12 | 04:11 pm
- FDA Approves COMETRIQ™ (Cabozantinib) For Treatment Of Progressive, Metastatic Medullary Thyroid Cancer - Business Wire 11.29.12 | 04:11 pm
- Exelixis Announces Webcasts Of Upcoming Investor Conference Presentations In November - Business Wire 11.05.12 | 04:11 pm
Partner Headlines for EXEL
- Four Biotech Stocks On The Clock - Seeking Alpha 02.19.13 | 09:02 am
- 5 Medical Stock Losers From Last Week With High Short Ratios - Seeking Alpha 12.22.12 | 06:12 am
- Biotech Weekly Recap: Loads Of Bullishness, 2 Giant Rallies, And Selling - Seeking Alpha 12.02.12 | 09:12 am
- Exel Presents Interim Data for Cabozantinib 40 mg Dose Cohort in Metastatic Castration-Resistant Prostate Cancer - Benzinga 09.30.12 | 11:09 am
- After Hours Most Active for Sep 4, 2012 : LYB, HT, SHLD, QQQ, KGC, MTL, CVH, BAC, EXEL, MSFT, FB, FRAN - NASDAQ 09.04.12 | 08:09 pm
- UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity Financing Dilution - Benzinga 08.20.12 | 01:08 pm
- Pre-Market Most Active for Aug 9, 2012 : EXEL, RBN, NOK, BAC, CSCO, ALLY^A, SIRI, AHL, QQQ, WIN, SPH, MNST - NASDAQ 08.09.12 | 12:08 pm
- FDA's Oncologic Drugs Advisory Committee to Review Exelixis New Drug Application for Cabozantinib November 9, 2012 - Benzinga 08.09.12 | 08:08 am
- Social Media Outlook for Monday July 30 (SHAW, BBY, EXEL, VHC) - Benzinga 07.30.12 | 01:07 pm
- Jim Cramer Watchdog: SELL Facebook and 'Buy, Buy, Buy' these 4 HOT Stocks - Wall St. Cheat Sheet 07.18.12 | 12:07 pm
